Leuprolide Acetate: Clinical Trials

28 trials of Leuprolide Acetate, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 5 active not recruiting, 4 terminated, 2 recruiting. 28 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 328Completed 14, Active not recruiting 5, Terminated 4, Recruiting 2, Unknown 2, Withdrawn 1
Phase 22Active not recruiting 1, Unknown 1

Follow Leuprolide Acetate: new trials by email Literature Review of Leuprolide Acetate trials Research Report on Leuprolide Acetate

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Relugolix, Leuprolide Acetate - Prostate Cancer
Phase 3CompletedSumitomo Pharma America, Inc.3872023-01-282026-06-15
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Enzalutamide, Rucaparib camsylate, Placebo - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3Active not recruitingAlliance for Clinical Trials in Oncology612021-10-142026-02-05
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
Darolutamide, Goserelin Acetate, Leuprolide Acetate - Prostate Carcinoma
Phase 3Active not recruitingECOG-ACRIN Cancer Research Group272021-03-012026-07-28
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Phase 3RecruitingECOG-ACRIN Cancer Research Group8042020-10-082026-11-13
GnRH Agonist at Embryo Transfer: IVF Outcomes
Saline Solution for Injection, Leuprolide Acetate - Infertility, Infertility, Female
Phase 3WithdrawnMaimonides Medical Center2019-04-152019-04-16
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Abiraterone, Bicalutamide, Degarelix - Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma
Phase 3RecruitingSWOG Cancer Research Network12732018-09-242026-10-08
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Relugolix, Leuprolide Acetate - Prostate Cancer
Phase 3CompletedMyovant Sciences GmbH11342017-04-182022-01-18
Management of Castration-Resistant Prostate Cancer with Oligometastases
Leuprolide Acetate, Goserelin Acetate, Triptorelin - Castration-resistant Prostate Cancer Patients with Oligometastases
Phase 2 / Phase 3Active not recruitingSir Mortimer B. Davis - Jewish General Hospital1022016-10-012024-12-04
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
Goserelin, Tamoxifen, Aromatase Inhibitors - Breast Cancer
Phase 3UnknownFirst Affiliated Hospital, Sun Yat-Sen University6802016-03-302023-01-17
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label - Hormone Sensitive Prostate Cancer, Prostate Cancer
Phase 3Active not recruitingPfizer10682014-12-172026-10-26
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
anastrozole, everolimus, exemestane - Breast Cancer
Phase 3Active not recruitingSWOG Cancer Research Network19392013-09-122026-10-23
Post-operative or Early Salvage XRT and ADT for High Risk PCa
antiandrogen therapy, leuprolide acetate, 3-dimensional conformal radiation therapy - Prostate Cancer
Phase 3TerminatedEuropean Organisation for Research and Treatment of Cancer - EORTC872009-10-012014-07-04
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer
bicalutamide, buserelin, flutamide - Prostate Cancer
Phase 3TerminatedNCIC Clinical Trials Group482008-06-022023-08-04
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
Leuprolide acetate 11.25 mg, Leuprolide acetate 30 mg - Puberty, Precocious
Phase 3CompletedAbbott842008-06-012011-11-02
Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
leuprolide acetate - Prostate Cancer
Phase 3TerminatedGP-Pharm202008-05-012010-09-09
Prevention of Obesity in Women Via Estradiol Regulation
leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training - Obesity
Phase 3CompletedUniversity of Colorado, Denver792008-05-012025-04-01
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
bicalutamide, goserelin acetate, leuprolide acetate - Gastrointestinal Complications, Prostate Cancer
Phase 3CompletedUniversity College, London42362007-11-012023-11-13
PROtecting Ovaries and Fertility During Chemotherapy - The PROOF Trial
Leuprolide acetate - Fertility Preservation, Cancer
Phase 3CompletedOttawa Hospital Research Institute302007-01-012017-04-05
Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer
leuprolide acetate - Prostate Cancer
Phase 3CompletedGP-Pharm1202005-09-012007-11-14
Lupron Sex Offender Therapy
leuprolide acetate - Pedophilia
Phase 2 / Phase 3UnknownSchober, Justine, M.D.102001-10-012005-09-22

Showing 20 of 28. Sign in to see all of them.

Conditions studied

Prostatic Neoplasms (18)  ·  Breast Neoplasms (4)  ·  Neoplasms (3)  ·  Breast Neoplasms, Male (1)  ·  Disease Susceptibility (1)  ·  Infertility (1)  ·  Infertility, Female (1)  ·  Infertility, Male (1)  ·  Metabolic Syndrome (1)  ·  Obesity (1)  ·  Pedophilia (1)  ·  Puberty, Precocious (1)  ·  Sexual Dysfunction, Physiological (1)

Sponsors

NCIC Clinical Trials Group (3)  ·  ECOG-ACRIN Cancer Research Group (2)  ·  GP-Pharm (2)  ·  SWOG Cancer Research Network (2)  ·  Abbott (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Eastern Cooperative Oncology Group (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  First Affiliated Hospital, Sun Yat-Sen University (1)  ·  Institute of Cancer Research, United Kingdom (1)  ·  M.D. Anderson Cancer Center (1)  ·  Maimonides Medical Center (1)  ·  Myovant Sciences GmbH (1)  ·  National Cancer Institute (NCI) (1)  ·  Ottawa Hospital Research Institute (1)

Countries

United States (18)  ·  Canada (9)  ·  United Kingdom (6)  ·  Austria (3)  ·  France (3)  ·  Italy (3)  ·  Slovakia (3)  ·  Spain (3)  ·  Australia (2)  ·  Brazil (2)  ·  China (2)  ·  Denmark (2)  ·  Finland (2)  ·  Germany (2)  ·  Netherlands (2)

Top investigators

A. O. Sartor, MD (1)  ·  Alicia K Morgans (1)  ·  Antonios Likourezos, M.P.H., M.A. (1)  ·  Arpit Rao, MD (1)  ·  Brian Chapin (1)  ·  Celestia S. Higano, MD (1)  ·  Christopher Parker, MD (1)  ·  Curtis A. Pettaway, MD (1)  ·  David G. McGowan, MD (1)  ·  George Wilding, MD (1)  ·  Helena Earl, MBBS, PhD, FRCP (1)  ·  John R. Yarnold, MD, FRCR (1)  ·  Justine M Schober, MD (1)  ·  Kim N. Chi, MD (1)  ·  Laurence H. Klotz, MD (1)

Results publications

PMID 38421243, PMID 10663329, PMID 17405995, PMID 17405996, PMID 19167733, PMID 20435244, PMID 21751904, PMID 22056152, PMID 22344198, PMID 22931259, PMID 25691677, PMID 25732157, PMID 26014295, PMID 29631362, PMID 31899823, PMID 33002429, PMID 33002431, PMID 33390282, PMID 34385241, PMID 34481017, PMID 35587650, PMID 35810050, PMID 37119051, PMID 37713020, PMID 37851874, PMID 38320143, PMID 38320501, PMID 38421252, PMID 38583574, PMID 38763153, PMID 38763154, PMID 38833643, PMID 39621968, PMID 40140551, PMID 40907514, PMID 41124201, PMID 41349040, PMID 41364813, PMID 41824265, PMID 42333826

NIH funding

U10CA180820 (2), 2017 (1), P30CA016672 (1), R01AG018198 (1), U10CA032102 (1), U10CA180821 (1), U10CA180888 (1)